Elutia Inc.

ELUT

US05479K1060

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 13:53:50 2024-06-11 EDT			5-day change	1st Jan Change
3.965 ^USD	+14.27%		+16.57%	+80.79%

05-09	Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-09	Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M	MT

Aziyo Biologics, Inc. Provides Preliminary Revenue Guidance for the Three Months Ended September 30, 2021

October 25, 2021 at 05:24 pm

Aziyo Biologics, Inc. provided preliminary revenue guidance for the three months ended September 30, 2021. The company announced preliminary revenue of approximately $11.5 million for the three months ended September 30, 2021, compared to $11.8 million a year ago.

Latest news about Elutia Inc.

Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M	05-09	MT
Transcript : Elutia Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Transcript : Elutia Inc., Q4 2023 Earnings Call, Mar 07, 2024	03-07
Elutia Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
Elutia Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Earnings Flash (ELUT) ELUTIA Posts Q4 Revenue $5.9M, vs. Street Est of $6.6M	03-07	MT
Transcript : Elutia Inc. - Special Call	02-08
Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance	12-18	CI
Elutia Inc. Amendments to Credit Agreement with SWK Funding LLC	11-15	CI
Cantor Fitzgerald Cuts Elutia's Price Target to $6 From $8, Keeps Overweight Rating	11-14	MT
Transcript : Elutia Inc., Q3 2023 Earnings Call, Nov 13, 2023	11-13
Elutia Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Earnings Flash (ELUT) ELUTIA Reports Q3 Revenue $6.1M, vs. Street Est of $7.3M	11-13	MT
Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. for $34.6 million.	11-07	CI
Top Premarket Gainers	23-10-06	MT
Elutia Inc. announced that it has received $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC	23-10-02	CI
Lake Street Initiates Elutia at Buy Rating With $3 Price Target	23-09-28	MT
GNI Group Plans to Buy Portion of Elutia's Orthobiologics Business	23-09-20	MT
Wall Street Set to Open Marginally Lower as Fed Kicks Off September Policy Meeting	23-09-19	MT
Equity Futures Trend Higher as Investors Expect No Rate Hike From Fed	23-09-19	MT
Top Premarket Gainers	23-09-19	MT
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms	23-09-19	DJ
Elutia Inc. announced that it expects to receive $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC and other investor	23-09-18	CI
Elutia Sells Orthobiologics Business Unit For Up to $35 Million	23-09-18	MT

Chart Elutia Inc.

Duration

Period

More charts

Company Profile

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Womenâs Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Womenâs Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Elutia Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.47 USD

Average target price

5 USD

Spread / Average Target

+44.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ELUTIA INC.	+80.79%	84.49M
CSL LIMITED	-0.12%	92.26B
SAMSUNG BIOLOGICS CO.,LTD.	-2.63%	38.11B
BIOGEN INC.	-12.55%	32.9B
UCB	+66.54%	26.51B
BIOMARIN PHARMACEUTICAL INC.	-13.04%	15.75B
INCYTE CORPORATION	-6.40%	13.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.50%	11.65B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.11%	10.12B
ALTEOGEN INC.	+187.82%	9.78B

Biopharmaceuticals

Elutia Inc.

Equities

ELUT

US05479K1060

Pharmaceuticals

Aziyo Biologics, Inc. Provides Preliminary Revenue Guidance for the Three Months Ended September 30, 2021

EPS Revisions